Xigadap M 10/500 Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Metformin 500 mg in an extended-release formulation. It is indicated for the management of type 2 diabetes mellitus in adults, particularly in patients inadequately controlled by diet and exercise alone or those requiring combination therapy. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion, thereby reducing plasma glucose levels independently of insulin secretion. Metformin, a biguanide, improves insulin sensitivity and decreases hepatic glucose production, contributing to better glycemic control. The extended-release formulation ensures a gradual release of metformin, enhancing gastrointestinal tolerability and improving patient compliance. Xigadap M 10/500 Tablet ER is typically administered once daily with meals to minimize gastrointestinal side effects. It is essential to monitor renal function prior to and during treatment, as both components are renally excreted. Common adverse effects may include urinary tract infections, genital mycotic infections, gastrointestinal disturbances, and rare cases of lactic acidosis. This medication should be used cautiously in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. Xigadap M 10/500 Tablet ER offers an effective dual mechanism approach for improved glycemic control in type 2 diabetes management.